You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series

Article metrics

Article menu

Download PDFPDF

XML
Original research
Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series

 

Online download statistics by month:

Online download statistics by month: July 2020 to March 2024

AbstractFullPdf
Jul 2020989745
Aug 2020838234
Sep 202010910720
Oct 2020363312
Nov 2020383820
Dec 2020434322
Jan 2021565230
Feb 2021303016
Mar 2021353320
Apr 2021181710
May 2021232014
Jun 2021232010
Jul 202118174
Aug 202119199
Sep 202111117
Oct 2021252417
Nov 2021242318
Dec 202117174
Jan 202230307
Feb 202217188
Mar 202217177
Apr 202213143
May 2022474913
Jun 202235355
Jul 202217162
Aug 202227274
Sep 2022404411
Oct 202232326
Nov 202220205
Dec 202218175
Jan 202315152
Feb 202339396
Mar 2023121410
Apr 202312120
May 2023883
Jun 20239100
Jul 2023662
Aug 2023553
Sep 202311112
Oct 2023111110
Nov 202317173
Dec 202310100
Jan 2024880
Feb 2024775
Mar 2024141419
Total12031189453